Diet and gastrointestinal bypass-induced weight loss: the roles of ghrelin and peptide YY
- PMID: 21292870
- PMCID: PMC3046841
- DOI: 10.2337/db10-0566
Diet and gastrointestinal bypass-induced weight loss: the roles of ghrelin and peptide YY
Abstract
Objective: Bariatric surgery causes durable weight loss. Gut hormones are implicated in obesity pathogenesis, dietary failure, and mediating gastrointestinal bypass (GIBP) surgery weight loss. In mice, we determined the effects of diet-induced obesity (DIO), subsequent dieting, and GIBP surgery on ghrelin, peptide YY (PYY), and glucagon-like peptide-1 (GLP-1). To evaluate PYY's role in mediating weight loss post-GIBP, we undertook GIBP surgery in PyyKO mice.
Research design and methods: Male C57BL/6 mice randomized to a high-fat diet or control diet were killed at 4-week intervals. DIO mice underwent switch to ad libitum low-fat diet (DIO-switch) or caloric restriction (CR) for 4 weeks before being killed. PyyKO mice and their DIO wild-type (WT) littermates underwent GIBP or sham surgery and were culled 10 days postoperatively. Fasting acyl-ghrelin, total PYY, active GLP-1 concentrations, stomach ghrelin expression, and colonic Pyy and glucagon expression were determined. Fasting and postprandial PYY and GLP-1 concentrations were assessed 30 days postsurgery in GIBP and sham pair-fed (sham.PF) groups.
Results: DIO progressively reduced circulating fasting acyl-ghrelin, PYY, and GLP-1 levels. CR and DIO-switch caused weight loss but failed to restore circulating PYY to weight-appropriate levels. After GIBP, WT mice lost weight and exhibited increased circulating fasting PYY and colonic Pyy and glucagon expression. In contrast, the acute effects of GIBP on body weight were lost in PyyKO mice. Fasting PYY and postprandial PYY and GLP-1 levels were increased in GIBP mice compared with sham.PF mice.
Conclusions: PYY plays a key role in mediating the early weight loss observed post-GIBP, whereas relative PYY deficiency during dieting may compromise weight-loss attempts.
Figures
Similar articles
-
Gastric bypass surgery restores meal stimulation of the anorexigenic gut hormones glucagon-like peptide-1 and peptide YY independently of caloric restriction.Surg Endosc. 2012 Apr;26(4):1086-94. doi: 10.1007/s00464-011-2004-7. Epub 2011 Nov 2. Surg Endosc. 2012. PMID: 22044971 Free PMC article.
-
Selective release of gastrointestinal hormones induced by an orally active GPR39 agonist.Mol Metab. 2021 Jul;49:101207. doi: 10.1016/j.molmet.2021.101207. Epub 2021 Mar 9. Mol Metab. 2021. PMID: 33711555 Free PMC article.
-
Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters.Ann Surg. 2006 Jan;243(1):108-14. doi: 10.1097/01.sla.0000183349.16877.84. Ann Surg. 2006. PMID: 16371744 Free PMC article.
-
Gut hormones as peripheral anti obesity targets.Curr Drug Targets CNS Neurol Disord. 2004 Oct;3(5):379-88. doi: 10.2174/1568007043336950. Curr Drug Targets CNS Neurol Disord. 2004. PMID: 15544446 Review.
-
Ghrelin, CCK, GLP-1, and PYY(3-36): Secretory Controls and Physiological Roles in Eating and Glycemia in Health, Obesity, and After RYGB.Physiol Rev. 2017 Jan;97(1):411-463. doi: 10.1152/physrev.00031.2014. Physiol Rev. 2017. PMID: 28003328 Free PMC article. Review.
Cited by
-
Bariatric surgery for diabetic comorbidities: A focus on hepatic, cardiac and renal fibrosis.Front Pharmacol. 2022 Oct 21;13:1016635. doi: 10.3389/fphar.2022.1016635. eCollection 2022. Front Pharmacol. 2022. PMID: 36339532 Free PMC article. Review.
-
Gastric inhibitory polypeptide (GIP) is selectively decreased in the roux-limb of dietary obese mice after RYGB surgery.PLoS One. 2015 Aug 12;10(8):e0134728. doi: 10.1371/journal.pone.0134728. eCollection 2015. PLoS One. 2015. PMID: 26266950 Free PMC article.
-
PYY is a negative regulator of bone mass and strength.Bone. 2019 Oct;127:427-435. doi: 10.1016/j.bone.2019.07.011. Epub 2019 Jul 12. Bone. 2019. PMID: 31306808 Free PMC article.
-
Altered ghrelin secretion in mice in response to diet-induced obesity and Roux-en-Y gastric bypass.Mol Metab. 2014 Aug 1;3(7):717-30. doi: 10.1016/j.molmet.2014.07.009. eCollection 2014 Oct. Mol Metab. 2014. PMID: 25353000 Free PMC article.
-
Effects of bariatric surgery on drug pharmacokinetics-Preclinical studies.Front Pharmacol. 2023 Apr 5;14:1133415. doi: 10.3389/fphar.2023.1133415. eCollection 2023. Front Pharmacol. 2023. PMID: 37089960 Free PMC article. Review.
References
-
- Karra E, Batterham RL. The role of gut hormones in the regulation of body weight and energy homeostasis. Mol Cell Endocrinol 2010;316:120–128 - PubMed
-
- Batterham RL, Cohen MA, Ellis SM, et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 2003;349:941–948 - PubMed
-
- Batterham RL, Heffron H, Kapoor S, et al. Critical role for peptide YY in protein-mediated satiation and body-weight regulation. Cell Metab 2006;4:223–233 - PubMed
-
- le Roux CW, Batterham RL, Aylwin SJB, et al. Attenuated peptide YY release in obese subjects is associated with reduced satiety. Endocrinology 2006;147:3–8 - PubMed
-
- Tsai AG, Wadden TA. Systematic review: an evaluation of major commercial weight loss programs in the United States. Ann Intern Med 2005;142:56–66 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases